EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Feasibility and acceptability of persons on long‐acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study

Elijah R Kakande, Laura B Balzer, Jane Kabami, James Ayieko iD, Gabriel Chamie iD, Nicole Sutter, Helen Sunday, Marilyn Nyabuti, Janice Litunya, Carol Camlin iD, Jason Johnson-Peretz, Jenny Temple und 6 weitere

Journal of the International AIDS Society · 2025

DOI: 10.1002/jia2.26465 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von Elijah R Kakande und 17 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Collaboration, Kampala, Uganda. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Patient Acceptance of Health Care, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIMH NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Injectable cabotegravir (CAB‐LA) is highly effective for HIV prevention, but real‐world implementation studies in Africa are ongoing. We assessed feasibility and acceptability among participants who used CAB‐LA in the SEARCH Dynamic Choice HIV Prevention extension study in rural Uganda and Kenya.

Methods

From January 2023 to December 2024, we followed females and males who were aged ≥ 15 years, with self‐assessed risk for HIV acquisition, in the intervention arm of the SEARCH Dynamic Choice HIV Prevention extension study, and received at least one CAB‐LA injection during the first 48 weeks. To assess the feasibility and acceptability of CAB‐LA, we designed quantitative surveys based on the Theoretical Framework for Acceptability. Surveys were administered at CAB‐LA initiation, after 24 and 48 weeks of use, and discontinuation of CAB‐LA.

Results

Of 487 intervention arm participants, 274 (56%) started CAB‐LA (183 females; 91 males; 79 youth aged 15–24 years). Of whom, 264 completed the survey at initiation, 206 after 24 weeks on CAB‐LA, 201 after 48 weeks on CAB‐LA and 69 at discontinuation of CAB‐LA. Most participants (65%; 171/264) reported choosing CAB‐LA because it was easier to take than pills, and nearly all (99%; 261/264) had limited knowledge of CAB‐LA prior to the study. Concerns for side effects were the largest anticipated and experienced barrier to CAB‐LA. Overall and with subgroups, satisfaction with CAB‐LA was high at 24 weeks (97%; 200/206) and 48 weeks (96%; 193/201). Nearly all participants reported that taking CAB‐LA was easy at 24 weeks (95%; 195/206) and 48 weeks (99%; 198/201). At CAB‐LA discontinuation, 83% (57/69) were likely to extremely likely to recommend CAB‐LA to a friend: 80% (20/25) of males, 84% (37/44) of females, 100% (19/19) of youth and 76% (38/50) of older adults.

Conclusions

In rural Uganda and Kenya, over half of participants in the SEARCH trial who were offered choice of oral PrEP/PEP or CAB‐LA chose and started CAB‐LA during the first 48 weeks. For both males and females and younger and older adults, CAB‐LA was both feasible and acceptable to deliver with satisfaction remaining high throughout the study, and nearly all reporting ease of use. Clinical Trial Number 05549726

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesPatient Acceptance of Health CareAnti-HIV AgentsHumansMaleFemaleUgandaKenyaLongitudinal StudiesAdultAdolescentYoung AdultRural PopulationFeasibility StudiesMiddle AgedDiketopiperazines

Stichwörter der Autor:innen

HIV preventionacceptabilitydynamic choicefeasibilityimplementationlong‐acting injectable cabotegravir

Substanzen

cabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Division of Biostatistics, University of California Berkeley, Berkeley, California, USA.
  • Kenya Medical Research Institute, Nairobi, Kenya.
  • Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
  • Department of Digital Innovation and Implementation Science, ViiV Healthcare, Durham, North Carolina, USA.
  • Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

ORCID-Profile: James Ayieko, Gabriel Chamie, Carol Camlin, Diane V Havlir

Förderung

  • NIAID NIH HHS
  • NIMH NIH HHS
  • NHLBI NIH HHS
  • U.S. National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Mental Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Kakande, E. R., Balzer, L. B., Kabami, J., Ayieko, J., Chamie, G., Sutter, N., Sunday, H., Nyabuti, M., Litunya, J., Camlin, C., Johnson-Peretz, J., Temple, J., Lavoy, G., Koss, C., Czarnogorski, M., Petersen, M. L., Kamya, M. R., & Havlir, D. V. (2025). Feasibility and acceptability of persons on long‐acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26465

Vancouver

Kakande ER, Balzer LB, Kabami J, Ayieko J, Chamie G, Sutter N, et al. Feasibility and acceptability of persons on long‐acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26465

BibTeX
@article{Kakande2025,
  author = {Kakande, Elijah R and Balzer, Laura B and Kabami, Jane and Ayieko, James and Chamie, Gabriel and Sutter, Nicole and Sunday, Helen and Nyabuti, Marilyn and Litunya, Janice and Camlin, Carol and Johnson-Peretz, Jason and Temple, Jenny and Lavoy, Geoff and Koss, Catherine and Czarnogorski, Maggie and Petersen, Maya L and Kamya, Moses R and Havlir, Diane V},
  title = {Feasibility and acceptability of persons on long‐acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study},
  journal = {Journal of the International AIDS Society},
  year = {2025},
  doi = {10.1002/jia2.26465}
}
Kostenlos starten →